In this issue:
Long-term imatinib for CML
Blinatumomab vs chemo for advanced ALL
ATRA + arsenic trioxide vs ATRA + chemo in non-high-risk APL
Number of extranodal sites predicts CNS relapse in DLBCL
Idelalisib + bendamustine and rituximab in R/R CLL
CART-30 cell therapy in R/R NHL
Pinatuzumab vedotin +/– rituximab in R/R NHL
AlloSCT after PD-1 blockade in R/R lymphoma
Discontinuation of dasatinib or nilotinib in CML
Lenalidomide maintenance in relapsed DLBCL ineligible for autoSCT
Please login below to download this issue (PDF)